JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

Workday (NASDAQ:WDAY – Get Free Report)‘s stock had its “market outperform” rating reiterated by research analysts at JMP ...

JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...

JMP Securities raised the firm’s price target on Cloudflare (NET) to $180 from $135 and keeps an Outperform rating on the shares. Cloudflare ...

Enova International (NYSE:ENVA – Free Report) had its target price upped by JMP Securities from $125.00 to $135.00 in a ...

JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

Covering some solid dividend stocks for JMP, analyst Aaron Hecht sees a reason to bet on higher value in the coming year. He notes that multiple tailwinds are coming together, and will likely lead ...

Wall Street analysts rerated Cloudflare, Inc (NYSE:NET) after the company released its fourth-quarterly print Thursday.

JMP Securities raised the price targets on Cloudflare (NET) and CyberArk Software (CYBR), while highlighting an industry ...

JMP Securities analyst Constantine Davides raised the firm’s price target on Option Care Health (OPCH) to $35 from $30 and keeps an Outperform rating on the shares amid a broader research note on ...

Google parent Alphabet Inc. has been downgraded to market perform from market outperform by JMP Securities, with the analyst firm highlighting the potential impact of the company’s antitrust battle.